Global Tumor Ablation Devices Market Overview:
The term tumor ablation is defined as the direct application of chemical non-energy or energy-based such as thermal and non-thermal therapies to eradicate or substantially destroy focal tumors. The term direct aims to distinguish these often applicator-based therapies from others that are applied orally or via an intravascular or peripheral venous route. Various thermal ablation includes RF, Microwave, Ultrasound and others.
- Increasing Occurrence of Chronic Diseases
- Growing Use of RF Ablation Catheter Devices
- Technological Development in Tumor Ablation such as Cryoablation Balloon Catheters
- High Cost Related to Tumor Ablation Devices
- Growing Awareness about the Benefits of Ablation Techniques
Some of the key players profiled in the report are St. Jude Medical, Inc. (United States), Medtronic plc (Ireland), Boston Scientific Corporation (United States), AngioDynamics, Inc. (United States), AtriCure, Inc. (United States), Conmed Corporation (United States), Smith & Nephew plc (United Kingdom), BTG plc (United Kingdom), Johnson & Johnson (United States), C.R. Bard, Inc. (United States), Elekta AB (Sweden), Hologic, Inc. (United States), Stryker Corporation (United States) and EDAP TMS S.A. (France). Additionally, following companies can also be profiled that are part of our coverage like Misonix, Inc. (United States) and Olympus Corporation (Japan). Analyst at AdvanceMarketAnalytics see United States Players to retain maximum share of Global Tumor Ablation Devices market by 2025. Considering Market by Functions, the sub-segment i.e. Automated will boost the Tumor Ablation Devices market.
On January 8, 2020 - Medtronic plc, announced that it has acquired Stimgenics, LLC, a privately-held company based in Bloomington, Illinois, that has pioneered a novel spinal cord stimulation (SCS) waveform known as Differential Target Multiplexed Spinal Cord Stimulation.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Tumor Ablation Devices market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Tumor Ablation Devices market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Tumor Ablation Devices, Suppliers of Tumor Ablation Devices, Wholesalers, Distributors and Retailers of Tumor Ablation Devices, Healthcare Industry and Governmental Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.